Who Paid My Doc
Empagliflozin and heart failure (HFpEF)
Research payments
$11,568,798
Through program year 2021, $11,568,798 in research payments was reported against Empagliflozin and heart failure (HFpEF), across 14,094 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharma GmbH & Co.KG; Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $2,201,336 | 2,518 |
| 2020 | Research | $3,182,674 | 4,605 |
| 2019 | Research | $6,184,788 | 6,971 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Harvey Serota Saint Louis, MO Named on 668 payments
- Matthew Budoff Torrance, CA Named on 363 payments
- Bhola Rama Marion, OH Named on 319 payments
- Alexander Paraschos Burlington, NC Named on 302 payments
- James Feldman Houston, TX Named on 293 payments
- Mark Napoli Monroe, LA Named on 259 payments
- Nabil Jarmukli Salem, VA Named on 252 payments
- Mohsin Alhaddad Jackson, TN Named on 241 payments
- Steven Lupovitch Arlington Heights, IL Named on 230 payments
- Vijay Mehta Elkhart, IN Named on 226 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.